期刊文献+

氟西汀合并奎硫平治疗躯体形式障碍的疗效 被引量:3

Comparison Study of Fluoxetine and Fluoxetine Combined with Quetiapine in Treatment of Somatoform Disorders.
下载PDF
导出
摘要 目的探讨氟西汀合并奎硫平治疗躯体形式障碍的疗效及安全性。方法70例躯体形式障碍患者随机分为两组,研究组以氟西汀合并奎硫平进行治疗,对照组单用氟西汀治疗,疗程均为8周。治疗前与治疗第2、8周采用症状自评量表(SCL-90),汉密尔顿抑郁量表(HAMD)评定临床疗效,副反应量表(TESS)评定不良反应。结果治疗后两组SCL-90,HAMD评分较治疗前减少,差异有显著性(P<0.01)。8周末研究组有效率88.2%,对照组有效率54.5%,两组差异有显著性(P<0.05)。并且在治疗2周末研究组较对照组见效快,差异有显著性(P<0.05)。两组不良反应均表现较轻,大多出现在治疗早期,经对症治疗逐渐缓解。结论氟西汀合并奎硫平治疗躯体形式障碍较单用氟西汀疗效好,起效快,且不增加副作用。 Objective To study the cliical effects and safety of Fluoxetine combined with quetiapine in treatment of somatoform disorders. Methods 67 patients were assigned to Fluoxetine (control group, n= 33) and Fluoxetine combined with quetiapine (study group, n=34), and treated for 8 weeks. Before treatment and at the ends of the 2th and 8th week after treatment, the clinical effects and side effects were assessed with SCL-90, HAMD, TESS. Results The score of SCL-90 and HAMD after the treatment of the study group and control group were lower than before treatment, which had a significant difference (P〈0. 01 ). At the end of 8th week, effective rates of the study group and control group were respectivly 88.2% and 54.5%, which bad a significant difference (P〈0.05). There was difference in the effective time of drugs of the two groups (P〈0.05), Side effeets of both the two groups were milder, most occurred in the initial stage of treatment and gradually remitted via expectant treatment. Conclusion Fluoxetine combined with quetiapine in treatment of somatoform disorders takes effects better and faster than single Fluoxetine and does't increase side effects.
出处 《中国健康心理学杂志》 2008年第7期798-799,共2页 China Journal of Health Psychology
关键词 氟西汀 奎硫平 躯体形式障碍 副反应 Fluoxetine Quetiapine Somatoform disorders Side effects
  • 相关文献

参考文献5

  • 1徐俊冕.躯体化与躯体形式障碍[J].中国行为医学科学,2004,13(3):359-360. 被引量:63
  • 2胡军,任朝晖,孙丽娟.躯体形式障碍45例就诊状况分析[J].中国行为医学科学,2002,11(1):54-54. 被引量:11
  • 3中华医学会精神科分会.中国精神障碍分类与诊断标准(CCMD-3).第3版,济南:山东科学技术出版社,2001:83-84.
  • 4张作记.行为医学量表手册[J].中国行为医学科学,2001,:118-119.
  • 5Rief W, Pilger F, lhle D, et al. Psychobiological aspects of somato form disorders: contributions of monoaminergic transmitter systems. Neuropsychobio, 2004,49 : 24-29.

二级参考文献11

  • 1颜文伟(译).精神障碍诊断统计手册(第4版)[J].上海精神医学,1994,6:21-21.
  • 2吴彩云 陈学诗.躯体型障碍.现代精神疾病治疗学[M].济南:山东科学技术出版社,1997.372-379.
  • 3中华医学会精神科分会.CCMD-3[M].济南:山东科技出版社,2001.97-99.
  • 4Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psychiatry,1988,145(11):1358-1368.
  • 5世界卫生组织ICD-10. 精神与行为障碍分类. 临床描述与诊断要点.范肖冬,汪向东等译.北京: 人民卫生出版社, 1993.129-135.
  • 6中华医学会精神科分会. CCMD-3. 中国精神障碍分类与诊断标准. 济南:山东科学技术出版社,2001.108-113.
  • 7Cassem NH: Functional Somatic Symptoms and somatoform disorders. in. Hackett TP. & Cassem NH (eds): Handbook of general Hospital psychiatry.PSG. Massachusetts 1987.126-153.
  • 8Ford CV. Somatoform and factitious disorder. In . Gabbard GO.(ed) Treatments of psychiatric disorders, 3rd ed ,2001.1731-1824.
  • 9Phillips KA. Somatoform and factitious disorder. American Psychiatric Publishing,Inc. 2001.1-88.
  • 10Hawton K , Salkovskis PM, Kirk J,et al. eds. Cognitive behaviour therapy for psychiatric problems. Oxford: Oxford Univ. Press,1989.235-276.

共引文献1014

同被引文献21

  • 1解克平,韩莹.西酞普兰与文拉法辛治疗抑郁症的对照观察[J].中国健康心理学杂志,2007,15(3):260-261. 被引量:5
  • 2邱亚峰,马丽霞.帕罗西汀治疗躯体化障碍的疗效[J].中国新药与临床杂志,2004,23(9):621-623. 被引量:14
  • 3陈静,陆峥.非典型抗精神病药治疗难治性抑郁症[J].上海精神医学,2004,16(5):301-303. 被引量:50
  • 4杨占宇,吕新华,刘建林,张文宝.文拉法辛治疗躯体形式障碍对照研究[J].临床心身疾病杂志,2006,12(4):262-263. 被引量:4
  • 5李一云,季建林.抑郁症病程慢性化的影响因素[J].国外医学(精神病学分册),1997,24(1):17-20. 被引量:24
  • 6Stoll A L, Rueter S. Treatment augmentation with opiates in severe and refractory major depression [J]. Am J Psychiatry, 1999, 156 (12) :2017.
  • 7Amasterdam J D, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression [J ]. J Psychiatr Clin Nomh Am, 1996,19 (2):371-386.
  • 8Aizenberg D. Mianserin, a 5-HT2a/2e and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors[J]. J Clin Neuropharmacol, 1997,20(3) : 210-214.
  • 9Zhang W. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamioe releasa in rat prefrontal cortex [J]. J Neuropsychopharmacology, 2000,23(3) :250-262.
  • 10David E A, Matt G K, Tamara A F. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors[J]. J Afect Disord, 2005,86 (1) : 99-104.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部